|
π
|
RECIST 1.1-Update and clarification: From the RECIST committee.
19 auth.
Lawrence H. Schwartz,
S. Litière,
E. D. de Vries,
R. Ford,
S. Gwyther,
S. Mandrekar,
L. Shankar,
J. Bogaerts,
A. Chen,
J. Dancey,
...
W. Hayes,
F. S. Hodi,
Otto S. Hoekstra,
Erich P. Huang,
N. Lin,
Yan Liu,
P. Therasse,
J. Wolchok,
L. Seymour
|
10 |
2016 |
10
π
|
|
π
|
Everolimus for advanced pancreatic neuroendocrine tumors.
17 auth.
James C. Yao,
M. Shah,
Tetsuhide Ito,
C. L. Bohas,
E. Wolin,
E. Van Cutsem,
T. Hobday,
T. Okusaka,
J. Capdevila,
E. D. de Vries,
...
P. Tomassetti,
M. Pavel,
S. Hoosen,
T. Haas,
J. Lincy,
D. Lebwohl,
K. Γberg
|
10 |
2011 |
10
π
|
|
π
|
Evidence Based Selection of Housekeeping Genes
10 auth.
H. J. de Jonge,
R. Fehrmann,
E. D. de Bont,
R. Hofstra,
F. Gerbens,
W. Kamps,
...
E. D. de Vries,
A. V. D. van der Zee,
G. T. te Meerman,
A. ter Elst
|
9 |
2007 |
9
π
|
|
π
|
A review on CXCR4/CXCL12 axis in oncology: no place to hide.
7 auth.
U. DomaΕska,
R. C. Kruizinga,
W. Nagengast,
H. TimmerβBosscha,
G. Huls,
E. D. de Vries,
...
A. Walenkamp
|
9 |
2013 |
9
π
|
|
π’
|
Metformin: taking away the candy for cancer?
7 auth.
M. Jalving,
J. Gietema,
J. Lefrandt,
S. de Jong,
A. Reyners,
R. Gans,
...
E. D. de Vries
|
8 |
2010 |
8
π’
|
|
π
|
Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study.
17 auth.
U. Banerji,
C. V. van Herpen,
C. Saura,
F. Thistlethwaite,
S. Lord,
V. Moreno,
I. Macpherson,
V. Boni,
C. Rolfo,
E. D. de Vries,
...
S. Rottey,
J. Geenen,
F. Eskens,
M. Gil-Martin,
E. Mommers,
N. Koper,
P. Aftimos
|
8 |
2019 |
8
π
|
|
π
|
Development and Characterization of Clinical-Grade 89Zr-Trastuzumab for HER2/neu ImmunoPET Imaging
9 auth.
Eli C F Dijkers,
J. Kosterink,
Anna P Rademaker,
L. Perk,
G. V. van Dongen,
J. Bart,
...
J. de Jong,
E. D. de Vries,
M. L. Lub-de Hooge
|
8 |
2009 |
8
π
|
|
π¬
|
Tumor-associated macrophages in breast cancer: Innocent bystander or important player?
Si-qi Qiu,
S. Waaijer,
M. C. Zwager,
E. D. de Vries,
B. van der Vegt,
C. SchroΜder
|
8 |
2018 |
8
π¬
|
|
π
|
In Vivo VEGF Imaging with Radiolabeled Bevacizumab in a Human Ovarian Tumor Xenograft
10 auth.
W. Nagengast,
E. D. de Vries,
G. Hospers,
N. Mulder,
J. de Jong,
H. Hollema,
...
A. Brouwers,
G. V. van Dongen,
L. Perk,
M. L. Lub-de Hooge
|
8 |
2007 |
8
π
|
|
π
|
Relevance of Tumor-Infiltrating Immune Cell Composition and Functionality for Disease Outcome in Breast Cancer
8 auth.
Rico D. Bense,
C. Sotiriou,
M. Piccart-Gebhart,
J. Haanen,
M. V. van Vugt,
E. D. de Vries,
...
C. SchroΜder,
R. Fehrmann
|
8 |
2017 |
8
π
|
|
π
|
Procalcitonin behaves as a fast responding acute phase protein in vivo and in vitro
12 auth.
M. Nijsten,
P. Olinga,
H. The,
E. D. de Vries,
H. Koops,
G. Groothuis,
...
P. Limburg,
H. T. ten Duis,
H. Moshage,
H. Hoekstra,
J. Bijzet,
J. Zwaveling
|
8 |
2000 |
8
π
|
|
π
|
Molecular and clinical characteristics of MSH6 variants: an analysis of 25 index carriers of a germline variant.
13 auth.
M. J. Berends,
Ying Wu,
R. Sijmons,
R. Mensink,
T. van der Sluis,
Jannet M Hordijk-Hos,
E. D. de Vries,
H. Hollema,
A. Karrenbeld,
C. Buys,
...
A. V. D. van der Zee,
R. Hofstra,
J. Kleibeuker
|
8 |
2002 |
8
π
|
